DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Financial Navigation Program Intervention in Supporting Patients With Solid Tumors and Their Caregivers

Not Applicable

Completed

Conditions: Caregiver
Solid Neoplasm

Interventions: Other: Educational Intervention
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2018-12-14

Last Posted Date: 2019-05-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03775616

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Phase 1

Terminated

Conditions: Other Skin

Interventions: Biological: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR
Drug: Avelumab
Biological: Pembrolizumab
Biological: Interferon Gamma-1b

First Posted Date: 2018-11-20

Last Posted Date: 2025-03-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 7

Registration Number: NCT03747484

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Pilot Trial of a Telephone Weight Loss, Nutrition, Exercise Study

Not Applicable

Completed

Conditions: Weight, Body
Weight Loss

Interventions: Behavioral: TALK control group
Behavioral: TALK study group

First Posted Date: 2018-11-13

Last Posted Date: 2021-01-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 105

Registration Number: NCT03738540

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort

Terminated

Conditions: Diabetes
Type2 Diabetes
Diabetes Mellitus

First Posted Date: 2018-11-06

Last Posted Date: 2025-04-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2269

Registration Number: NCT03731637

Locations: 🇺🇸
Univeristy Hospital, Indiana University Health, Indianapolis, Indiana, United States
🇺🇸
Kaiser Permanente Southern California, Los Angeles, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

and more 15 locations

Resistance Training Program and Cardiovascular Exercise in Increasing Muscle Mass in Adolescent and Young Adult Stem Cell Transplant Survivors

Not Applicable

Completed

Conditions: Malignant Neoplasm

Interventions: Behavioral: Exercise Intervention
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Behavioral: Telephone-Based Intervention

First Posted Date: 2018-09-17

Last Posted Date: 2020-11-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT03672981

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia in Remission
Recurrent Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndrome With Excess Blasts
Chronic Myelomonocytic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Bone Marrow Transplantation
Drug: Mycophenolate Mofetil
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Fludarabine Phosphate
Drug: Tacrolimus
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Biospecimen Collection

First Posted Date: 2018-09-14

Last Posted Date: 2025-05-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03670966

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Phase 1

Terminated

Conditions: Metastatic Leiomyosarcoma
Metastatic Undifferentiated Pleomorphic Sarcoma
Refractory Undifferentiated Pleomorphic Sarcoma
Advanced Synovial Sarcoma
Advanced Undifferentiated Pleomorphic Sarcoma
Advanced Leiomyosarcoma
Metastatic Synovial Sarcoma
Refractory Leiomyosarcoma
Refractory Round Cell Liposarcoma
Refractory Soft Tissue Sarcoma

Interventions: Drug: Itacitinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2018-09-13

Last Posted Date: 2024-05-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 27

Registration Number: NCT03670069

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Phase 2

Withdrawn

Conditions: Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome
Myelofibrosis
Recurrent Hodgkin Lymphoma
Therapy-Related Acute Myeloid Leukemia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic and Lymphoid System Neoplasm
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Non-Hodgkin Lymphoma

Interventions: Biological: Anti-Thymocyte Globulin
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2018-07-27

Last Posted Date: 2021-06-30

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT03602898

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)

Not Applicable

Completed

Conditions: Cancer
Smoking

Interventions: Behavioral: Standard of care smoking cessation smartphone app
Behavioral: Experimental smoking cessation smartphone app

First Posted Date: 2018-07-26

Last Posted Date: 2019-12-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 59

Registration Number: NCT03600038

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Pilot Trial of the First Conversational Agent for Smoking Cessation (QuitBot)

Not Applicable

Completed

Conditions: Smoking Cessation

Interventions: Behavioral: Delayed access to novel novel messaging program intervention
Behavioral: Immediate access to novel messaging program intervention
Behavioral: Immediate access to standard of care messaging program intervention

First Posted Date: 2018-07-12

Last Posted Date: 2020-12-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 404

Registration Number: NCT03585231

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy